Clinics in Laboratory Medicine 1995: Vol 15 Index

23 Pages·1995·3.7 MB·English

CUMULATIVE INDEX 1995
Volume 15
March THROMBOSIS AND HEMOSTASIS FOR THE CLINICAL
LABORATORY: PART II, pages 1-208
June CONTEMPORARY ISSUES IN CLINICAL
MICROBIOLOGY, pages 209-453
September GYNECOLOGIC PATHOLOGY, pages 455-777
December GENETIC TESTING, pages 779-1023
Note: Page numbers of article titles are in boldface type.
ABI Prism DNA Sequencer, 820, 823 Adenoid cystic carcinoma, cervical,
Abortion, spontaneous, antiphospholipid 504-505
antibodies in, 74-75, 98 Adenoid squamous cell carcinoma, vulvar,
Abscess, amebic, examination of, 323-324 476
fine-needle aspiration of, 257, 261 Adenomatoid tumor, ovarian, 604-605
Accounting, tools for, 185-186 Adenomyoma, uterine, 536-537, 548-
Acid-fast bacilli, identification of. See 549
Mycobacterial diseases, diagnosis of. Adenosarcoma, uterine, 532-536, 549-
Acquired immunodeficiency syndrome. 551
See Human immunodeficiency virus Adenosine deaminase measurement, in
infection. mycobacterial diseases, 290
Acremonium infections, 374-376 Adenovirus, identification of, 397, 400
Actinomyces, identification of, 350 AE antibodies, in gynecologic disease
in fine-needle aspirates, 267 diagnosis, 728-729
Activated partial thromboplastin time, in Aerotolerance tests, in anaerobe
heparin therapy monitoring, 110-112 identification, 352
in lupus anticoagulant syndrome, 66 Agglutination tests, in viral identification,
Activated protein C co-factor defect, 130 392
Active programmable electronic matrix, Aggregometer, in platelet dysfunction, 21,
for DNA sequencing, 825 24-25
Activity ratio, 191 Aggressive angiomyxoma, vulvar, 482-
Acute urethral syndrome, diagnosis of, 484
historical aspects of, 238-239 Agnogenic myeloid metaplasia, platelet
screening for, 240-241 dysfunction in, 13
Adenocarcinoma, cervical, immuno- AIDS. See Human immunodeficiency virus
histochemical techniques in, 731-732 infection.
microinvasive, 498-500 Albumin, meconium, in cystic fibrosis
endometrial, endometrioid, 519-523 screening, 888
immunohistochemical techniques in, Alcohol abuse, platelet dysfunction in, 16
732-733 Alkaline phosphatase, placental, in
villoglandular, 520-521 gynecologic tumors, 735, 737
ovarian, 734-736 Allele-specific oligonucleotide screening,
Adenofibroma, uterine, 546-548 804
Adenoid basal carcinoma, cervical, Alpha-fetoprotein, in ovarian tumor
503-504 diagnosis, 734
1002 CUMULATIVE INDEX 1995
Alternaria infections, 378 Anaphylatoxin, as hemostasis activation
mycotoxins in, 381-382 marker, 44
Alzheimer’s disease, genetic testing for, Anemia, hemolytic, antiphospholipid
920-922 antibodies in, 97
ethical issues in, 992-993 refractory, with excessive blasts, platelet
Amebiasis, diagnosis of, 321-324 dysfunction in, 13
Ameboma, 321 sideroblastic, platelet dysfunction in, 13
Aminolevulinic acid, accumulation of, in Angelman syndrome, genetic testing for,
porphyria, 944-945 852-853
Amplification techniques, 785-786, Angiography, hemostasis activation
795-815. See also Polymerase chain markers in, 48-49
reaction. Angiomyofibroblastoma, vulvar, 464
for RNA, 826-827 Angiomyxoma, aggressive, vulvar, 482-484
polymerase chain reaction in, 807 Angiotensin converting enzyme, as
self-sustained sequence replication in, hemostasis activation marker, 44
809 Antibiotic susceptibility testing, in
in first polar body analysis, 811-812 pneumonia, sputum Gram stain
in preimplantation diagnosis, 810-813 information in, 217-219
in sex chromosome analysis, 810-811 Antibodies, antiphospholipid. See
in viral identification, 392-394 Antiphospholipid antibody(ies).
ligase chain reaction, 807-808 in disease diagnosis. See Immunohisto-
novel, 826-833 chemical techniques.
self-sustained sequence replication, 809 Anticardiolipin antibody(ies), actions of, 70
strand displacement, 809-810 assays for, 69, 87-92, 101
Amyloid precursor protein gene, mutation concentrations in, 89
of, in Alzheimer’s disease, 921-922 in infections, 97-98
Amyloid-B protein, in Alzheimer’s disease, in pregnancy, 98
921 in systemic lupus erythematosus, 94,
Amyotrophic lateral sclerosis, genetic 96, 100
testing for, 918-920 in thrombocytopenia, 97
ethical issues in, 992-993 isotypes in, 90-91
Anaerobes, 333-364 problems with, 88-89
common, 340 subclasses in, 91-92
description of, 334-335 co-factor for, 89-90
ecology of, 336-337 definition of, 86
identification of, colony characteristics in autoimmune disorders, 96-97
in, 349-350, 352-353 phospholipid binding to, 67
cultivation of, 348 systemic lupus erythematosus and,
differential agar media in, 349, 351 73-74
direct examination in, 343-347 vs. lupus anticoagulant, 69-70
fatty acid analysis in, 357-358 Anticardiolipin antibody test, 69
incubation in, 348 Anticardiolipin syndrome, cardiac disease
indications for, 358-359 in, 71-72
isolation media for, 347-348 classification of, 67-68, 76-78
laboratory capability for, 358-359 clinical presentations of, 78-79
metabolic product analysis in, 357-358 diagnosis of, 79
morphologic features in, 349-350, 352- drug-induced, 79
353 neurologic disorders in, 73
purpose of, 341 obstetric complications in, 74-75
rapid kits for, 355-357 postpartum, 75
specimen collection and handling for, thrombosis in, 70-71
342 treatment of, 76-78
subculture of, 348-349 vs. lupus anticoagulant syndrome, 63-
traditional biochemical tests for, 351,
354-357 Antinuclear antibodies, hemostasis
infections with, 337-339 activation markers with, 53-54
bacteremia, 338-339 Antioxidants, in amyotrophic lateral
pneumonia, 220 sclerosis, 920
predisposing factors for, 340-341 Antiphospholipid antibody(ies), 85-108
taxonomy of, 335-336 assays for, 87-93, 101
CUMULATIVE INDEX 1995 1003
antigens in, 89-90 Apolipoprotein H, in antiphospholipid
clinical value of, 102 antibody binding, 89-90
concentrations in, 89 Arias-Stella reaction, 506, 508, 527
in autoimmune disorders, 96-97 Arthritis, psoriatic, antiphospholipid
in infections, 97-98 antibodies in, 96
in livedo reticularis, 99 Aspergillus infections, fine-needle
in pregnancy, 98 aspiration in, 262-263, 268
in systemic lupus erythematosus, 94, in concurrent fungal infections, 381
96, 100 a mycotoxins in, 381-382
in thrombocytopenia, 97 Aspiration, fine-needle. See Fine-needle
in vascular thrombosis, 99 aspiration.
isotypes in, 90-91 of ovary. See Ovary.
lupus anticoagulants, 92-93 gastric, specimen from, in mycobacterial
populations for, 94-101 identification, 284-285
problems with, 88-89 suprapubic, in urinary infection diagno-
standards for, 89 sis, 243
subclasses in, 91-92 Aspirin, in anticardiolipin syndrome,
co-factor for, 89-90 74-75
pathogenesis of, 86-87 Aspirinlike defect, of platelets, 7, 9
types of, 85-86 ATB Anaerobes ID system, in anaerobe
Antiphospholipid syndromes, 63-84 identification, 357
anticardiolipin antibodies in, 69-79 Atherosclerosis, hemostasis activation
cardiac disease and, 71-72 markers in, 47-48
classification of, 76-78 Athrombia, essential, 5-6
clinical presentations of, 78-79 Atypical polypoid adenomyoma, uterine,
collagen vascular disease and, 73-74 536-537, 548-549
cutaneous manifestations of, 72-73 Atypical squamous epithelium of
neurologic disorders in, 73 undetermined significance, cervical,
obstetric syndromes and, 74-75 694, 696-697
thrombosis and, 69-71 Autoimmune disorders, antiphospholipid
classification of, 67-68, 76-78 antibody assay in, 96-97
definition of, 86 antiphospholipid syndrome in, treat-
diagnosis of, 79 ment of, 68
hemostasis activation markers in, 44, platelet dysfunction in, 17
52-53 Automation, of DNA sequencing, 818-821
livedo reticularis in, 99 productivity of, 195-196
lupus anticoagulant in, 64-69
populations susceptible to, 101
systemic lupus erythematosus with, 94,
BACTEC system, for mycobacterial
treatment of, 102-103 culture, 291-292
types of, 63-64 for NAP test, in mycobacterial identifi-
Antithrombin(s), actions of, 133-134 cation, 293
concentrates of, for antithrombin defi- Bacteremia, in mycobacterial diseases,
ciency, 141-142 288-289
deficiencies of, 133-142 Bacteroides, 340
absence form, 136 identification of, 350
acquired, 137-141 Bartholin’s gland, carcinoma of, 481
dysfunctional form, 136 Basal cell carcinoma, vulvar, 478-479
hereditary, 135-137 Basiloid squamous cell carcinoma, vulvar,
in heparin therapy, 113 475
in pregnancy, 142 Becker muscular dystrophy. See Muscular
‘prevalence of, 152 dystrophies (Duchenne and Becker).
treatment of, 141-142 Bernard-Soulier syndrome, 4-5
API An-IDENT test, in anaerobe Bethesda system, in Pap smear
identification, 356 classification, 693-694
API-20A kits, in anaerobe identification, Bifidobacterium, identification of, 350
355 Biochemical tube tests, in anaerobe
Apolipoprotein E gene, mutation of, in identification, 351, 354-357
Alzheimer’s disease, 922 Biomek system, for DNA sequencing, 820
1004 CUMULATIVE INDEX 1995
Biopsy, fine-needle. See Fine-needle Carcinoid tumors, ovarian, 601-602, 719,
aspiration. 721
liver, in mycobacterial diseases, 287 Carcinoma. See also Adenocarcinoma.
lung, in pneumonia, 229-230 adenoid basal, cervical, 503-504
Bipolaris infections, 378 adenoid cystic, cervical, 504-505
Blastomyces infections, fine-needle Bartholin’s gland, 481
aspiration in, 262-263, 268 basal cell, vulvar, 478-479
Blastoschizomyces capitatus infections, cervical. See Cervical lesions.
377-378, 381 ciliated, endometrial, 520, 522
Bleeding, in platelet dysfunction, 1-38 clear cell, endometrial, 523, 525, 527
in thrombolytic therapy, control of, 176 ovarian, 718
Blood, examination of, in mycobacterial embryonal, 721, 723
diseases, 288-289 endometrial. See Endometrial tumors.
Blood agar, in anaerobe identification, endometrioid, ovarian, 588-589, 717-718
347-348 glassy cell, cervical, 500-502
Blood protein defects, in thrombosis, lymphoepithelioma-like, cervicai, 501-
125-163 503
activated protein C co-factor, 130 metastatic, ovarian, 724
antithrombins, 133-142 mucinous, endometrial, 525-526
fibrinolytic system, 144-149 ovarian. See Ovarian neoplasms, carci-
heparin co-factor II, 142-144 noma. :
in homocystinemia and papillary, endometrial, 527-528
homocystinuria, 150-151 secretory, endometrial, 520
plasminogen, 146-147 serous, endometrial, 523-524
prevalence of, 151 small cell, immunohistochemical tech-
protein C, 126-130 niques in, 738
protein S, 130-133 ovarian, 605-607
tissue plasminogen activator and squamous cell. See Squamous cell carci-
inhibitor, 147-149 noma. :
Bone marrow specimen, examination of, in transitional cell, ovarian, 589-591
mycobacterial diseases, 287 undifferentiated, endometrial, 526
Bowenoid papulosis, vulvar, 461-462 verrucous, vulvar, 475-476, 729
Branched DNA technology, 823-833 vulvar. See Vulvar lesions.
BRCA genes, in hereditary breast cancer, Carcinosarcoma, uterine, 529-532, 551-
962-963 554 _
Break-even analysis, 186-188 Cardiolipin, antibodies to. See
Breast cancer, genetic testing in, 962-965 Anticardiolipin antibody(ies).
ethical issues in, 991-992 Cardiopulmonary bypass surgery, platelet
hereditary, 962-963 dysfunction in, 13-14
sporadic, 963-965 Carriers, of genetic diseases, DNA testing
Brenner tumors, 718, 736-737 of, 847
Bronchoalveolar lavage specimen, in fragile X syndrome, 851,861
mycobacterial infections, 285 Catalase test, in anaerobe identification,
in pneumonia, 222-229 3520 ;
Budgeting, tools for, 186 Catheterization, urinary, for sample
collection, in infection diagnosis,
243-247
CD62 molecule, measurement of, in
CA-125 antigen, in gynecologic tumors, platelet dysfunction, 27-28
735-736, 744-745, 748 Cell culture, in chlamydial infections,
CAM antibodies, in gynecologic disease 667-668
diagnosis, 728-729 in herpes simplex virus infections, 677—
Cancer, breast. See Breast cancer. 678
colorectal. See Colorectal cancer. Cellular leiomyoma, uterine, 568
Candida infections, fine-needle aspiration Centrifugation, in viral culture, 394
in, 262, 268 Cerebrospinal fluid, examination of, in
in concurrent fungal infections, 381 mycobacterial diseases, 286-287
typing in, 425 Cervical lesions, 493-516
Carcinoembryonic antigen, antibodies to, adenocarcinoma, 498-500, 731-732
in gynecologic disease diagnosis, 730 Arias-Stella reaction, 506, 508
CUMULATIVE INDEX 1995 1005
atypical squamous epithelium of unde- Chorangiocarcinoma, 656, 658
termined significance, 694, 696-697 Chorangiosis, 624-626
carcinoma, adenoid basal, 503-504 Choreoathetosis, in Huntington’s disease,
adenoid cystic, 504-505 915-916
advanced, treatment of, 761-763 Choriocarcinoma, 658, 660-662
early stage, treatment of, 757-761 Chromatography, in anaerobe
glassy cell, 500-502 identification, 347, 357-358
human papillomavirus and, invasive, in mycobacterial identification, 295
7 Chromosomal DNA, restriction
morphologic changes in, 694-698 endonuclease analysis of, in
pathogenetic mechanisms in, 687— microorganism typing, 418-419
689, 692-693 Chromosome painting, in DNA
immunohistochemical techniques in, hybridization, 785
729-730 Chromosomes, gene mapping on, 980-981
lymphoepithelioma-like, 501-503 sex, amplification of, 810-811
squamous cell, microinvasive, 493-497 Chromotrope method, for gastrointestinal
treatment of, 757-763 parasite identification, 313-314
classification of, Bethesda system in, Ciliated carcinoma, endometrial, 520, 522
693-694 CIN. See Cervical lesions, intraepithelial
cystic endocervical tunnel clusters, 509- neoplasia.
511 Clear cell carcinoma, endometrial, 523,
histology of, 494-497 525, 527
immunohistochemical techniques in, ovarian, 718
729-732 Clear-cell hidradenoma, vulvar, 463
intraepithelial neoplasia, human papillo- Cloning, of genes, in human genome
mavirus and, epidemiology of, project, 982-984
692-693 Clostridium, 340
high-grade squamous, 696-699 identification of, 350
low-grade squamous, 695-696, 698— Clostridium difficile, identification of,
699 343-346
immunohistochemical techniques in, Coagulopathy, placental vascular lesions
729-730 in, 616-617
invasion of, immunohistochemical tech- Coccidia, identification of, 314-321
niques in, 730-731 Coccidioides infections, fine-needle
large loop excision of transformation aspiration in, 262, 264, 268
zone in, 511-512 College of American Pathologists,
mesonephric remnant hyperplasia, 505- Workload Recording Method of,
506 183-184
placental site nodule, 508-509 Colorectal cancer, genetic testing in,
precancerous, human papillomavirus in, 958-962
694-695 ethical issues in, 991-992
sexually transmitted. See Sexually trans- hereditary, 958-959
mitted diseases. sporadic, 959-962
C,-esterase inhibitor, as hemostasis Condom catheters, urine sample collection
activation marker, 44 with, in infection diagnosis, 247
Charge couple device, for DNA Condyloma acuminata, human
sequencing, 826 papillomavirus and. See Human
Chédiak-Higashi syndrome, 6-7 papillomavirus.
Chemotherapy, for cervical cancer, Contig, in gene mapping, 981
760-761, 763 Contraceptives, oral, antithrombin defects
for gestational trophoblastic disease, related to, 139-140 :
756-757 Contrast media, hemostasis activation
for ovarian cancer, advanced, 745-749 markers generated by, 49-50
borderline, 750-752 Contribution margin, 198
germ cell, 753 Coronary artery bypass graft occlusion,
Chips, DNA, 823, 825-826 anticardiolipin antibodies in, 71
Chlamydial infections, diagnosis of, Corpus luteum, fine-needle aspiration
665-671 cytology of, 712
Chloride transport, defective, in cystic Corticosteroids, in lupus anticoagulant
fibrosis, 878 syndrome, 68
1006 CUMULATIVE INDEX 1995
Cost analysis, 196-197 in viral identification, 390
Cost ratio analysis, 197 Cytomegalovirus, identification of, 270,
Cresyl fast violet method, for DNA 397-398
detection, 833-834 Cytopathic effects, detection of, in viral
Cross-reacting immunological material- identification, 394
positive porphyria, 945-946 Cytotrophoblast, pathology of, in
Cryptococcus neoformans infections, 381 gestational trophoblastic disease,
fine-needle aspiration in, 262, 264, 269 633-634
Cryptosporidium, identification of, 315-321
Culture, of anaerobes, 348
of fine-needle aspirate, 254-255
of mycobacteria, 291-292
of sputum, in pneumonia, 219-220 Decidual cells, vs. trophoblasts, 738
correlation with Gram stain, 212- Dego’s disease, antiphospholipid
213 antibodies in, 72
of urine. See Urine specimens, for infection Dematiaceous fungal infections, 378-379
diagnosis. Dementia, in Alzheimer’s disease,
of viruses, rapid techniques for, 394-395 diagnosis of, molecular techniques in,
supplementary, in infection epidemiol- 920-922
ogy and control, 411 Denaturing gradient gel electrophoresis, in
Culture media, in anaerobe identification, acute intermittent porphyria, 952
347-348 Diabetes mellitus, placental vascular
Culturette test, for Clostridium difficile lesions in, 617
detection, 346 Diarrhea, from parasites, diagnosis of. See
Curvularia infections, 378 Gastrointestinal parasites, identification
of.
Cycling probe reaction, 832-833
Cyclospora, identification of, 315-320 Differential agar media, in anaerobe
Cyst(s), of Entamoeba histolytica, identification, 349, 351
identification of, 323 Dilute Russell’s viper venom time, in
ovarian, fine-needle aspiration cytology lupus anticoagulant detection, 66-67,
of, 710, 712-713 92-93
Cystathionine beta synthase deficiency, Direct fluorescent antibody tests, in
thrombosis in, 150-151 chlamydial infections, 668-669
Cystic endocervical tunnel clusters, Disk tests, in anaerobe identification, 352
509-511 Disseminated intravascular coagulation,
Cystic fibrosis, 877-898 hemostasis activation markers in,
clinical features of, 878-879 51-52, 57-58
genetic counseling on, 890-891 in antithrombin deficiency, 140-142
genotype-phenotype correlations in, DNA, amplification of, methods for. See
- 887-888 Amplification techniques.
laboratory diagnosis of, 879 analysis of, direct tests for, 844-846
pathology of, 878-879 in infection epidemiology and control,
screening for, in neonates, 888-890 415-421
Cystic fibrosis transmembrane indirect tests for, 843-844
conductance regulator gene, logistics of, 842-847
identification of, 879-880 novel methods of, 817-837
multiplex oligonucleotide ligation assay automated sequencing in, 818-823
of, 827-829 chips in, 823, 825-826
mutation analysis of, 880-887 detection methods for, 833-834
recommendations for, 891-893 for amplification, 826-833
structure of, 880 sequence analysis, 817-818
Cystic struma ovarii, 603-604 types of, 842-847
Cystoscopy, in urine sample collection, for chips of, 823, 825-826
infection diagnosis, 243 denaturation (melting) of, 781
Cytoclone procedure, for Clostridium electrophoresis of, 783-784
difficile detection, 346 hybridization of, 781-782
Cytogenetic testing, logistics of, 847-849 in gestational trophoblastic disease, 631-
Cytology, fine-needle aspiration, of ovary. 633, 642-644
See Ovary, fine-needle aspiration cytology large segment changes in, 790-791
of
minisatellite, 789
CUMULATIVE INDEX 1995 1007
nucleotide sequence identification in. in acute intermittent porphyria, 952
See Human genome project. in cystic fibrosis screening, 889-890
purification of, 782-783 in DNA analysis, 783-784
restriction enzyme digestion of, 783 in Gaucher disease diagnosis, 905
satellite, in short tandem repeat polymor- multilocus enzyme, in microorganism
phism analysis, 979 typing, 414
selfish, 973 pulsed-gel, in microorganism typing,
sequencing of, 817-818 420
automated, 818-823 temperature gradient, 806
direct, 807 Embryonal carcinoma, ovarian, 721, 723
in human genome project, 984-985 Emericella nidulans infections, 379, 381
methods for, 786 Employees, productivity of, management
storage of, 783 of, 193-195
structural, 789 Encephalitozoon, identification of, parasites,
structure of, 780-782 312
transfer methods for, 784-785 Endocervical glands, cystic tunnel clusters
DNA mismatch chemical cleavage, of, 509-511
802-803 Endometrial glands, elements of, in
Dot blot methods, 785 uterine neoplasms, 560
in cystic fibrosis transmembrane conduc- Endometrial tumors, 517-543
tance regulator gene analysis, 882 adenocarcinoma, 519-523
Drugs, anticardiolipin syndrome from, 79 immunohistochemical techniques in,
lupus anticoagulant from, 65 732-733
platelet dysfunction from, 18-20, 22-23 villoglandular, 520-521
Duchenne muscular dystrophy. See adenosarcoma, 532-536
Muscular dystrophies (Duchenne and Arias-Stella reaction, 527
Becker). atypical polypoid adenomyoma, 536-537
Dysfibrinogenemia, congenital, thrombosis carcinoma, ciliated, 520
in, 149
classification of, 517
prevalence of, 152 clear cell, 523, 525, 527
Dysfibrinolysis, thrombosis in, 144-149 differential diagnosis of, 527-528
Dysgerminoma, ovarian, 721 grading of, 528-529
Dystrophin gene, mutations of, in hyperplasia with, 517-518
muscular dystrophy, 929-933 immunohistochemical techniques in,
Dysuria-pyuria syndrome, 238
732
mucinous, 525-526
papillary, 527-528
Echinococcus granulosus, identification of, secretory, 520
270 serous, 523-524
Economic tools, 179-201 squamous cell, 526
definition of, 180 staging of, 528-529
financial management, 185-192 undifferentiated, 526
information management, 182-184 carcinosarcoma, 529-532, 551-554
marketing techniques, 198-200 hormone receptors in, 560-562
productivity improvement, 193-196 metaplastic, 537-540
profitability analysis, 197-198 sex cord elements in, 559-560
revenue-generating, 196-197 stromal, 555-562, 732
types of, 180-182 treatment of, 754-756
E6/E7 oncoproteins, of human Endometrioid tumors, endometrial,
papillomavirus, interactions with adenocarcinoma, 519-523
tumor suppressor gene products, ovarian, 717-718
688-689 carcinoma, 588-589, 717-718
Egg yolk reactions, in anaerobe intermediate, 586-588
identification, 352 Endometriosis, fine-needle aspiration
Elderly persons, heparin therapy cytology of, 713
monitoring in, 115 Endometrium, hyperplasia of, carcinoma
Electron microscopy, in viral identification, with, 517-518
390-391 in gestational trophoblastic disease,
Electrophoresis, denaturing gradient, 634, 637
804-806 tumors of. See Endometrial tumors.
1008 CUMULATIVE INDEX 1995
Endothelin, as hemostasis activation Familial adenomatous polyposis, of colon,
marker, 43-44 genetic testing in, 958
Endovasculitis, hemorrhagic, placental, Fatty acids, analysis of, in anaerobe
622-624 identification, 357-358
Entamoeba histolytica, identification of, 270, Feces, analysis of, for gastrointestinal
321-324 parasites. See Gastrointestinal parasites,
Enterococcus, typing of, 424-425 identification of.
Enterocytozoon, identification of, 311-313 Ferrocene method, for DNA detection, 833
Enterotoxins, Clostridium difficile, detection Fetus, loss of, with anticardiolipin
of, 345-346 antibodies, 74-75, 98
Enteroviruses, identification of, 399 placental circulation of, vascular disor-
Enzyme immunoassays, for ders of, 620-626
antiphospholipid antibodies, 89 twin, in molar pregnancy, 638-640
Fibrinogen, concentration of, measurement
in chlamydial infections, 669
in Clostridium difficile identification, 345- of, in thrombolytic therapy
346 monitoring, 172
in viral identification, 392 degradation products of, as hemostasis
Enzyme-linked immunosorbent assay, in activation markers, 43
Clostridium difficile identification, 344 in platelet dysfunction, 13-17
in Entamoeba histolytica identification, 322 Fibrinolysis, defects of, thrombosis in,
in mycobacterial diseases, 289 144-149
Epidemiology, of infections, molecular primary, hemostasis activation markers
techniques in. See Molecular techniques, in, 57-58
Fibrinopeptide, as hemostasis activation
in infection epidemiology and control.
Epithelial components, in uterine marker, 42
Fibrosis, fine-needle aspiration of, 257
mesenchymal tumors, 545-554, 733 Filariae, fine-needle aspiration of, 270
Epsilon aminocaproic acid, in thrombolytic
Financial management tools, 185-192
therapy reversal, 174-175 Financial ratio analysis, 190-192
c-erbB-2 gene, in breast cancer, 963-964 Fine-needle aspiration, in infection
in colorectal cancer, 960 diagnosis, 251-278
Esculin hydrolysis test, in anaerobe acute inflammatory, 256-257
identification, 352 chronic inflammatory, 257-258
Esterase test, in urinary tract infections, granulomatous, 258-260
241 historical aspects of, 252-253
Estrogen receptors, in endometrial stromal microorganism identification in,
tumors, 560-562 261-270
Ethanol abuse, platelet dysfunction in, 16 necrotic, 260-261
Ethical issues, in genetic engineering, 993 opportunistic, 271-272
in genetic testing, 989-999 overview of, 251-252
for cancer susceptibility, 991-992 procedure for, 253-256
for cardiovascular disease, 990-991 specimens obtained from, morphology
for degenerative diseases, 992-993 of, 256-261
information from, right to use, 997- processing of, 253-256
999 stains for, 255-256
potential benefits and, 994-995 vs. neoplasm, 258
results communication and, 995-997 of ovary. See Ovary.
in human genome project, 985-987 First polar body analysis, 811-812
Ethyl acetate, in gastrointestinal parasite Flotation technique, in gastrointestinal
identification, 309 parasite identification, 309
Eubacterium, identification of, 350 Flow cytometry, in gestational
Exons, definition of, 787 trophoblastic disease, 642
Exophiala jeanselmei infections, 381 Fluorescence in situ hybridization
Exserohilum infections, 378 techniques, in cytogenetic testing,
848-849
Fluorescence labeling, in DNA sequencing,
820
Factor Xa, inhibition of, lupus Fluorescent methods, in anaerobe
anticoagulant in, 66 identification, 352
Factor XII deficiency, thrombosis in, in gastrointestinal parasite identification,
148-149 317-318
CUMULATIVE INDEX 1995 1009
in viral identification, 390-391 mycotoxins in, 381-382
Fluorochrome method, for gastrointestinal Fusobacterium, 340
parasite identification, 314 identification of, 350
FMR1 gene, in fragile X syndrome, FXR1 gene, related to FMR1 gene, 867
862-868
Folate deficiency, platelet dysfunction in,
18
Follicular cysts, fine-needle aspiration Gas chromatography, in anaerobe
cytology of, 710, 712 identification, 357-358
Fonsecaea infections, 379, 381 in mycobacterial identification, 295
Foreign bodies, inflammation from, vs. Gastric aspiration, specimen from, in
infection, 265 mycobacterial identification, 284-285
Fractional allelic loss, in tumor suppressor Gastrointestinal parasites, identification of,
genes, 961 307-331
Fragile X syndrome, 859-876 coccidia, 314-321
carriers of, 861 Cryptosporidium, 315-321
causes of, 859-860 Cyclospora, 315-320
clinical features, 860-861 Encephalitozoon, 312
FMR1 gene in, 862-868 Entamoeba histolytica, 321-324
molecular diagnosis of, 851-852, 869-873 Enterocytozoon, 311-313
molecular nature of, 862-865 Giardia lamblia, 308-310
Fungal infections, 365-387 Isospora belli, 315-317
Acremonium in, 374-376 methods for, 308-310
adventitious fungi in, 366 microsporidia, 310-314
Alternaria in, 378, 381-382 Sarcocystis, 314-316
Aspergillus in, 262-263, 268, 381-382 Gastrointestinal viruses, identification of,
Bipolaris in, 378 400
Blastoschizomyces capitatus in, 377-378, Gaucher disease, 899-913
381 enzymatic diagnosis of, 900-901
Candida in, 262, 268, 381, 425 gene of, mutation analysis of, 903-907
concurrent, 381 genetic counseling in, 908-909
Cryptococcus neoformans in, 262, 264, 269, genotype-phenotype correlations in,
381 907-908
Curvularia in, 378 molecular diagnosis ot, 901-903
dematiaceous fungi in, 378-379 recommendations for, 909-910
emergent pathogens causing, 367-368 subtypes of, 899
Emericella nidulans in, 379, 381 treatment of, 910
Exophiala jeanselmei in, 381 Gene therapy, for muscular dystrophy,
Exserohilum in, 378 937-938
fine-needle aspiration in, 262, 268-269 Genetic counseling, ethical aspects of,
Fonsecaea in, 379, 381 995-997
Fusarium in, 368-373, 381-382 in cystic fibrosis, 890-891
in HIV infection, 368 in Gaucher disease, 908-909
concurrent, 381 logistics of, 855
Penicillium marneffei in, 380 Genetic engineering, ethical issues in, 993
mycotoxin production in, 381-382 Genetic mapping, 791-792
Paecilomyces lilacinus in, 373-374 in human genome project, 976-979
Penicillium marneffei in, 380 Genetic testing, amplification methods in,
Phialophora parasitica in, 379 795-815
pneumonia, 220 DNA analysis in, 817-837
Prototheca wickerhamii in, 381 efficiency of, strategies for, 839-857
Pseudallescheria boydii in, 381 genetic counseling and, 855
Pseudomicrodochium suttoni in, 381 in metabolic diseases, 840-841
recent trends in, 366-367 in newborn population, 842
Rhinocladiella atrovirens in, 379 test selection for, 849, 851-855
Scedosporium prolificans in, 376 with cytogenic methods, 847-849
Sporothrix schenckii in, 380 with molecular techniques, 842-847
Trichosporon beigelii in, 377-378 ethical issues in, 989-999
Wangiella dermatitidis in, 381 human genome project and, 973-988
Fusarium infections, 368-373 in acute intermittent porphyria, 943-956
1010 CUMULATIVE INDEX 1995
Genetic testing (Continued) Gonadotropin hormone-releasing hormone
in Alzheimer’s disease, 920-922 agonists, uterine leiomyoma and,
in amyotrophic lateral sclerosis, 918-920 567-568
in cancer, 957-971 Gonorrhea, diagnosis of, 672-675
ethical issues in, 991-992 Gram stain, of sputum. See Sputum
in cardiovascular disease, ethical issues examination.
in, 990-991 Granular cell tumors, vulvar, 464
in cystic fibrosis, 877-898 Granulomatous inflammation, fine-needle
in degenerative diseases, ethical issues aspiration of, 258-260
in, 992-993 Granulosa cell tumors, ovarian, 718
in fragile X syndrome, 859-876 Gynecologic pathology, cervical lesions.
in Gaucher disease, 899-913 See Cervical lesions.
in Huntington’s disease, 915-918 endometrial tumors. See Endometrial tu-
in muscular dystrophies, 927-941 mors.
in neurodegenerative disorders, 915-926 gestational trophoblastic disease, 631-
methods for, 779-794 664
preimplantation, 810-813 human papillomavirus infections, 685-
privacy issues in, 997-998 704
Genital warts, human papillomavirus and. immunohistochemical approaches in,
See Human papillomavirus. 727-742
Genome project, human. See Human oncologic disease, 743-770
genome project. ovarian neoplasms. See Ovarian neo-
Genomic organization, 786-789 plasms.
information flow in, 786-788 placental vascular lesions, 611-629
minisatellite DNA in, 789 sexually transmitted diseases, 665-684
supragenes in, 788-789 uterine neoplasms. See Uterine neoplasms.
Germ cell tumors, ovarian, 599-604, 737 vulvar lesions. See Vulvar lesions.
fine-needle aspiration cytology of,
719-723
treatment of, 753
Gestational trophoblastic disease, 631-664 Hemoglobinuria, paroxysmal nocturnal,
choriocarcinoma, 658, 660-662 platelet dysfunction in, 13
classification of, 632 Hemolytic anemia, antiphospholipid
hydatidiform mole, complete, 632-644 antibodies in, 97
diagnosis of, 633, 642-644 Hemorrhagic endovasculitis, placental,
early, 637-638 622-624
invasive, 641 Hemostasis, activation of, molecular
natural history of, 640-641 markers of, 39-61
pathology of, 633-638 actions of, 40-41
‘with normal twin, 638-640 antiphospholipid syndrome and, 44
immunohistochemical techniques in, assays for, 46-47, 54-55, 59-60
738 biological fluids containing, 59
partial, 644-649 chemical natures of, 45-46
hydropic abortus, 649-650 in angiography, 48
immunohistochemical techniques in, 738 in antiphospholipid syndrome,
placental site lesions, chorangiocarci- 52-53, 57-58
noma, 656, 658-659 in atherosclerosis, 47-48
nodules, 508-509, 650-654 in contrast media use, 49-50
trophoblastic tumor, 655-657 in disseminated intravascular
treatment of, 756-757 coagulation, 51-52, 57-58
Glanzmann’s thrombasthenia, 5-6 in immune thrombocytopenic
Glassy cell carcinoma, cervical, 500-502 purpura, 57-58
Glial fibrillary acidic protein, antibodies to, in malignancy, 57-58
in gynecologic disease diagnosis, 732 in myocardial infarction, 57-58
Glucocerebrosidase deficiency. See Gaucher in pregnancy, 47-48
disease. in primary fibrinolysis, 57-58
Glucosylceramide, accumulation of. See in stress, 50-51
Gaucher disease. in stroke, 57-58
Glutamic acid decarboxylase test, in in thrombotic thrombocytopenic
anaerobe identification, 352 purpura, 57-58